25/02/2022
⚠️ New Guidelines on Liver Cancer ⚠️
🚨New guideline alert! Gastroenterology has published new AGA guidelines only recommending systemic therapy for HCC in advanced stage C liver patients. See our HCC systemic therapy recommendations below.
⭐️Systemic therapies are only recommended for patients with advanced HCC not amenable to surgical or radiological treatment but with preserved liver function. First line treatments include atezolizumab/bevacizumab, sorafenib, and lenvatinib with atezolizumab/bevacizumab showing modest improvement over sorafenib and thus considered first.
⭐️For second line treatment, recommendations were made for cabozantinib, pembrolizumab, ramucirumab, and regorafenib recognizing that this is an area of great limitation with likely more data in future studies.
⭐️Systemic therapy are not recommended for patients with poor liver function.
⭐️Systemic therapy are not recommended as adjuvant therapy for HCC.
To read the guidance visit this link: https://gastro.org/news/just-published-aga-guideline-on-systemic-therapy-for-hepatocellular-carcinoma-hcc/
